CLAIMS

1. A pharmaceutical composition that is adapted/formulated for parenteral administration in the form of a solution comprising

i) apomorphine as the active substance;

ii) a water miscible co-solvent;

iii) an anti-oxidant; and

iv) water,

wherein the pH of the composition is greater than 4.

2. The composition of claim 1 wherein the amount of active ingredient is between about 10 to 70 mg/ml, preferably between 10 - 65 mg/ml.

3. The composition according to one of the preceding claims wherein the amount of co-solvent alone or in mixture thereof is between 0.1 to 80 % and more preferably is selected between 0.2 to 70 %.

4. The composition according to one of the preceding claims wherein the co-solvent is selected from an alcohol or a polyol or a polyether or a mixture thereof, preferably from polyols and polyethers or a mixture thereof.

5. The composition according to one of the preceding claims wherein the co-solvent is selected from diols, triols, cyclodextrin derivatives, polyethylene glycols and polyethylene glycol derivatives or a mixture thereof.

6. The composition according to one of the preceding claims wherein the antioxidant is selected from acids and their salts, vitamins and vitamin derivatives, amino acids, sulfites or free phenolic radical scavengers, and preferably from acids and their salts, and sulfites.

7. The composition according to one of the preceding claims wherein the antioxidant is selected from ascorbic acid and sodium metabisulfite.

8. The composition according to one of the preceding claims wherein a surfactant is optionally present in the composition.

9. The composition of claim 8 wherein a surfactant is present in the composition.

10. The composition of claim 9 wherein the surfactant has a HLB between 8 and 20 and more preferably between 12 to 17.

11. The composition of claim 9 or 10 wherein the surfactant is selected from polyoxyethylene sorbitan fatty ester(s) or polyethylene glycol derivatives or poloxamers.

12. The composition according to one of the preceding claims wherein the apomorphine : co-solvent ratio (w:w) is between 1:0.1 to 1:40 and preferably between 1:0.2 and 1:30.

13. The composition according to one of the preceding claims wherein the pH of the composition is between 4 and 7, preferably between 5 and 7.

14. The composition according to one of the preceding claims wherein a pH modifier is present in the composition.

15. The composition according to claim 14 wherein the pH modifier is selected from sodium hydroxide, sodium bicarbonate, potassium hydroxide or magnesium hydroxide.

16. The composition according to one of the preceding claims which is suitable to be administered by subcutaneous route, and preferably administered by a subcutaneous infusion.

17. The composition according to one of the preceding claims 1 to 16 for use as medicament intended to reduce "off episodes" in patients with advanced Parkinson’s disease.

18. Use of a composition according to one of the preceding claims 1 to 16 in the preparation of an injection solution, for the treatment of Parkinson’s disease.

19. A process for the manufacture of a composition according to one of the preceding claims 1 to 16, said process being defined by the following steps with the order below:

i) The optional surfactant is weighed followed by the co-solvent in the same container.

ii) The antioxidant is weighed (alone) and dissolved in degassed water.

iii) The antioxidant solution is added to the co-solvent alone or to a mixture of co-solvent with surfactant under agitation.

iv) A quantity of degassed water is added and then the solution is adjusted to around pH 7.5 ± 0.5 and more preferably close to pH 7.

v) The apomorphine is weighed and introduced into the above solution and agitated until complete dissolution takes place.

vi) The pH is controlled and adjusted if necessary according to the pH values as defined in claim 13, using a pH modifier.

vii) Finally, the remaining quantity of degassed water is added to reach the required volume.